Advair Diskus Powder
Product Images NDC 50090-4502

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair Diskus (NDC 50090-4502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)

Chemical structure diagram displaying the molecular arrangement of fluticasone propionate, one of the active ingredients in ADVAIR DISKUS (fluticasone propionate and salmeterol). The structure includes labeled atoms and stereochemistry relevant to the compound's identity.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)

Chemical structure diagram depicting the active ingredients in ADVAIR DISKUS: fluticasone propionate and salmeterol. The image shows molecular formulas with characteristic rings and functional groups for these compounds used in respiratory inhalation powder. No other textual information is present.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)

A line graph depicting the percentage change in FEV1 over 12 weeks and endpoint for ADVAIR DISKUS 100/50 twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph shows each treatment's effect on FEV1 across the study duration with corresponding sample sizes listed below the x-axis.*

FDA Label Image

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)

This line graph shows the percentage change in FEV1 over time in hours on the x-axis and percent change on the y-axis for four groups: patients using ADVAIR DISKUS 100/50 twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. Data indicates lung function response within a 12-hour period following dosing.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)

A line graph depicting the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period following administration of ADVAIR DISKUS 100/50 (twice daily), Salmeterol 50 mcg (once daily), Fluticasone propionate 100 mcg (twice daily), and Placebo. Data points show varying response curves for each treatment group with distinct markers.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)

A line graph showing percent change in FEV1 over a 24-week period comparing ADVAIR DISKUS 250/50, Salmeterol 50 mcg, and placebo. The x-axis represents weeks, and the y-axis represents percent change in FEV1. Data points for each treatment group are shown with different symbols, and sample sizes are listed below the graph at various time points.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)

A line graph depicting the percentage change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo groups. The x-axis represents time in days and weeks, and the y-axis shows percent change in FEV1. The graph illustrates trends in lung function across treatment groups during the study period.*

FDA Label Image

Figure A (Advair Diskus Spl Graphic 08)

An illustrative diagram of an ADVAIR DISKUS inhaler device showing labeled parts including the outer case, mouthpiece, lever, thumb grip, and counter. The label on the device indicates a strength of 100/50 micrograms of fluticasone propionate and salmeterol in powder form for respiratory inhalation.*

FDA Label Image

Figure B (Advair Diskus Spl Graphic 09)

An instructional illustration showing a person holding and sliding the purple ADVAIR DISKUS inhaler, demonstrating the proper technique to prepare the device for inhalation.*

FDA Label Image

Figure C (Advair Diskus Spl Graphic 10)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler device. The image highlights the proper grip and an arrow indicating the direction to open or operate the inhaler for inhalation use of the powder medication.*

FDA Label Image

Figure D (Advair Diskus Spl Graphic 11)

An illustration showing a woman demonstrating the use of a purple inhaler device, resembling ADVAIR DISKUS, by holding it near her mouth and preparing to inhale the medication.*

FDA Label Image

Figure E (Advair Diskus Spl Graphic 12)

An illustration showing a woman using a purple ADVAIR DISKUS inhaler by bringing it to her mouth for respiratory inhalation. The image demonstrates the proper use technique for this powder inhaler device containing fluticasone propionate and salmeterol.*

FDA Label Image

Figure F (Advair Diskus Spl Graphic 13)

An instructional illustration showing hands holding an ADVAIR DISKUS inhaler. One hand is gripping the inhaler while the other is pulling the lever to the left, demonstrating the action to prepare the device for inhalation.*

FDA Label Image

Figure G (Advair Diskus Spl Graphic 14)

An illustration showing a woman performing an oral hygiene rinse by swishing liquid in her mouth over a sink, with a glass of water nearby.*

FDA Label Image

Figure H (Advair Diskus Spl Graphic 15)

ADVAIR DISKUS dry powder inhaler labeled 100/50 mcg strength containing fluticasone propionate and salmeterol. The label indicates 60 blisters per package and highlights use by information. The inhaler is purple with a rounded design and a dose counter marked in red.*

FDA Label Image

Label Image (Lbl500904502)

Label for ADVAIR DISKUS 250 mcg/50 mcg inhalation powder by A-S Medication Solutions. Each blister contains 250 mcg fluticasone propionate and 50 mcg salmeterol base. The label provides storage instructions, package size of 60 blisters, and distributor information in Libertyville, IL. Includes a barcode and dosing note to see package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.